Pembrolizumab and Olaparib for Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy
Clinicaltrials.gov identifier:
NCT04666740
Treatment study for people diagnosed with metastatic pancreatic cancer with Homologous Recombination Deficiency, or whose disease has responded well to first-line or second-line platinum therapy
Pembrolizumab and Olaparib for People With Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy
About the Study
NOTE: This study is no longer recruiting people.
This is a study for people diagnosed with pancreatic cancer with , or whose disease has responded well to or second-line platinum therapy. The goal of this study is to look at whether combining the drug, pembrolizumab and the , is a more effective treatment for this cancer than taking alone.
NOTE: This study is no longer recruiting people.
NOTE: This study is no longer recruiting people.